Skip to main content
. 2021 Aug 30;17(4):898–904. doi: 10.4103/1673-5374.323077

Figure 7.

Figure 7

Effect of the lentivirus carrying siRNA for P2X4R on the protein expression levels of P2X4R (A), NLRP3 (B), caspase-1 (C), IL-1β (D), and IL-18 (E) in the substantia nigra pars compacta.

Data are expressed as mean ± SEM (n = 8 mice/group). **P < 0.01, vs. control group; ††P < 0.01, vs. P2X4R-RNA group; ‡‡P < 0.01, vs. P2X4R-NC + 6-OHDA group; &&P < 0.01, vs. P2X4R-NC group; $$P < 0.01, vs. P2X4R-NC group (one-way analysis of variance followed by the Student-Newman-Keuls test). Control group: After 1 week of pretreatment with 0.9% physiological saline, ascorbic acid was injected into the SNpc stereotactically; 6-OHDA group: after 1 week of pretreatment with 0.9% physiological saline, 6-OHDA was injected into the SNpc stereotactically to establish PD; P2X4R-NC group: after 1 week of pretreatment with a negative control lentivirus (NC), ascorbic acid was injected into the SNpc stereotactically; P2X4R-NC + 6-OHDA group: after 1 week of pretreatment with the negative control lentivirus, 6-OHDA was injected into the SNpc stereotactically; P2X4R-siRNA group: after 1 week of pretreatment with a lentivirus carrying siRNA targeting P2X4R, ascorbic acid was injected into the SNpc stereotactically; P2X4R-siRNA + 6-OHDA group: after 1 week of pretreatment with the lentivirus carrying siRNA targeting P2X4R, 6-OHDA was injected into the SNpc stereotactically. 6-OHDA: 6-Hydroxydopamine; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; IL: interleukin; NC: negative control lentivirus; NLRP3: Nod-like receptor family protein 3; P2X4R: P2X4 receptor; PD: Parkinson’s disease; siRNA: small-interfering RNA; SNpc: substantia nigra pars compacta.